Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...

Colossal Biosciences, the biotech company behind plans to try to bring back the woolly mammoth, Tasmanian tiger and the dodo, raised another $200 million for its research.

The World Economic Forum predicts that biodiversity loss could cause a colossal decline in global GDP of $2.7 trillion ...

Most of the mammoths died out about 10,000 years ago ... On evolutionary timescales they disappeared only a moment ago, but bringing them back is no easy feat. "We have animal operations ...

Colossal aims to revive the woolly mammoth species ... s better to prevent extinctions in the first place, rather than bring back bio-replicas whose ‘reintroduction’ may have a host of ...

Based on these encouraging results, Lamm says he believes bringing back woolly mammoths is likely to have a similarly positive effect. 'We feel confident that, in general, a more diverse ecosystem ...

Among its first rewilding goals: bringing back the woolly mammoth. The last, isolated mammoth populations died out 4,000 years ago, with their extinction blamed on hunting by humans and climate ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it.

Colossal Biosciences announced Wednesday it had raised $200 million in Series C funding round led by TWG Global for its mission to bring back the woolly mammoth, dodo and thylacine (also commonly ...

Colossal has made headlines in the past for its plans to bring back the woolly mammoth, the thylacine — commonly referred as the Tasmanian tiger — and the dodo bird. The Texas-based company ...